Genome-based pharmacogenetics and the pharmaceutical industry

Nat Rev Drug Discov. 2002 Jul;1(7):541-9. doi: 10.1038/nrd840.


Pharmacogenetic capabilities have changed markedly since The SNP Consortium made a dense single-nucleotide polymorphism (SNP) map freely available in 2001. For more than 40 years, pharmacokinetics and pharmacodynamics of drug-metabolizing molecules were the focus of practical applications. Today, it is possible to use SNP-mapping technologies to create a genetic profile of each individual that can be used to identify patterns of susceptibility genes for common diseases as well as genetic risk/efficacy factors that are related to the effects of drugs.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Dideoxynucleosides / adverse effects
  • Drug Industry*
  • Genetic Predisposition to Disease
  • Genome
  • Humans
  • Pharmacogenetics*
  • Polymorphism, Single Nucleotide*
  • Proteome


  • Dideoxynucleosides
  • Proteome
  • abacavir